Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-PSMA-11 vs 18F-Fluorocholine PET in Prostate Cancer Recurrence
NCT03623425Phase 3Unknown
- Sponsor
- CHRU de Nancy - Hôpital Central
- Start
- Feb 2019
- Primary completion
- May 2020
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial (2 arms), sponsored by CHRU de Nancy - Hôpital Central. Primary endpoint: Number of lesions characteristic for prostate cancer detected by each TEP imaging method at 3 months. Status: unknown.
Beyond the preview
Go deeper on NCT03623425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03623425.